secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apogee Therapeutics, Inc. (APGE)
CIK:        0001974640
Form:       8-K
Filed at:   2024-12-10T23:59:59+00:00
Accession:  0001104659-24-127004
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Apogee doses first healthy volunteers in Phase 1 trial of TSLP antibody APG333
------------------------------------------------------------------------------

- APG333 is a novel half-life extended monoclonal antibody targeting TSLP for asthma, COPD, and I&I conditions.
- Phase 1 trial: double-blind, placebo-controlled, single-ascending dose in ~32 healthy volunteers across 4 cohorts.
- Interim safety and pharmacokinetic data expected in second half of 2025.
- Preclinical proof-of-concept achieved for APG777+APG333 combination; clinical trial planning underway in asthma and COPD.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1974640/000110465924127004/0001104659-24-127004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1974640/000110465924127004/tm2430568d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-127004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer